Editorials |
From the University of Pennsylvania School of Medicine (K.B.H.), Heart Failure and Transplantation, Philadelphia; and the Mayo Clinic (J.C.B.), Rochester, Minn.
Correspondence to Dr Kenneth B. Margulies, University of Pennsylvania School of Medicine Heart Failure and Transplantation, 709 Stellar Chance Laboratories, 422 Curie Boulevard, Philadelphia, PA 19104. E-mail ken.margulies@uphs.upenn.edu
See related article, pages 183190
Key Words: dendroaspis natriuretic peptide heart failure natriuretic peptide receptor-A autoradiography
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
Since the discovery of atrial natriuretic factor 25 years ago,1 there has been an explosion of research elucidating the basic biology of endogenous natriuretic peptides. Among other things, this work has established atrial natriuretic factor as one of a family of structurally similar endogenous natriuretic peptides with complex and distinct functional roles in maintaining normal homeostasis and responding to pathological circumstances.
The first identified member of this family, atrial natriuretic peptide (ANP), is synthesized and secreted in the cardiac atria under normal conditions and by the ventricular myocardium during fetal development, hypertrophy, or heart failure. BNP, a distinct natriuretic peptide first isolated from the porcine brain, is preferentially synthesized and secreted by ventricular cardiac myocytes and, like ANP, exhibits increased expression during hypertrophy and heart failure. In contrast, C-type natriuretic peptide (CNP) is mainly produced by vascular endothelial cells and neurons, whereas urodilatin is synthesized and secreted by renal cells. The last identified member of this peptide family is dendroaspis natriuretic peptide (DNP), which was first isolated from the venom of the Green Mamba snake.2 Although immunoreactivity to DNP has been identified in several human tissues3 and circulating plasma,4 the gene encoding this natriuretic peptide has not yet been identified within the human genome.
Actions of natriuretic peptides are mediated through binding to 3 distinct natriuretic peptide receptors (NPRs) that are located on the cell surface and bind endogenous ligands with varying specificities and affinities (Figure).5 Two of the receptors, NPR-A and NPR-B, have an extracellular (ligand-binding) domain
Related Article:
Circ. Res. 2006 99: 183-190.
This article has been cited by other articles:
![]() |
M. William, E. J. Hamilton, A. Garcia, H. Bundgaard, K. K. M. Chia, G. A. Figtree, and H. H. Rasmussen Natriuretic peptides stimulate the cardiac sodium pump via NPR-C-coupled NOS activation Am J Physiol Cell Physiol, April 1, 2008; 294(4): C1067 - C1073. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kilic, A. Bubikat, B. Gassner, H. A. Baba, and M. Kuhn Local Actions of Atrial Natriuretic Peptide Counteract Angiotensin II Stimulated Cardiac Remodeling Endocrinology, September 1, 2007; 148(9): 4162 - 4169. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |